Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-03-2020 | Glaucoma | Glaucoma

Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR

Authors: Keijiro Ishikawa, Ri-ichiro Kohno, Kenichiro Mori, Yusuke Murakami, Shintaro Nakao, Masato Akiyama, Shigeo Yoshida, Koh-Hei Sonoda

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 3/2020

Abstract

Purpose

To investigate periostin (PN) and tenascin-C (TNC) expression in the aqueous humor and trabeculectomy specimens of patients with neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR).

Methods

This study enrolled 37 eyes of 37 patients who were grouped into (1) NVG secondary to PDR (NVG; n = 8); (2) PDR without NVG (PDR; n = 9); (3) primary open-angle glaucoma (POAG; n = 11); and (4) cataract surgery patients as a control group (CG; n = 9). Aqueous humor samples were collected from the anterior chamber at the start of surgery or intravitreal injection of anti-VEGF drug. The concentrations of PN, TNC, VEGF, and TGF-β2 (transforming growth factor-beta 2) were measured by ELISA. Sclerostomy tissues containing trabecular meshwork were obtained from two NVG patients and a POAG patient who underwent trabeculectomy surgery. Immunohistochemical analyses were performed to determine the localization of PN and TNC expression in the sclerostomy tissues.

Results

PN and TNC-C levels were below detection threshold in the POAG and CG groups. The NVG group had significantly higher levels of PN and TNC compared with the PDR group (84.7 ng/ml vs 2.2 ng/ml and 18.5 ng/ml vs 4.6 ng/ml, respectively; p < 0.05). There was a significant correlation between the levels of PN and TNC-C in the NVG group (r = 0.86, p < 0.05). We found significant expression of PN in the trabecular meshwork and Schlemm’s canal of sclerostomy tissues excised from patients with NVG.

Conclusions

Increased PN and TNC expression suggests their possible involvement in the pathogenesis of NVG secondary to PDR.

Havens SJ, Gulati V (2016) Neovascular glaucoma. Dev Ophthalmol 55:196–204CrossRef

Shazly TA, Latina MA (2009) Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 24(2):113–121CrossRef

Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T (2010) Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 150(2):223–229 e221CrossRef

John T, Sassani JW, Eagle RC Jr (1983) The myofibroblastic component of rubeosis iridis. Ophthalmology 90(6):721–728CrossRef

Miao H, Hou X, Hwang DK, Tao Y (2018) Vascular endothelial growth factor, basic fibroblast growth factor, and pigment epithelium-derived factor expression in the neovascular iris in retinal diseases. J Ophthalmol 2018:8025951PubMedPubMedCentral

Yu XB, Sun XH, Dahan E, Guo WY, Qian SH, Meng FR, Song YL, Simon GJ (2007) Increased levels of transforming growth factor-betal and -beta2 in the aqueous humor of patients with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 38(1):6–14CrossRef

Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP (1998) Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105(2):232–237CrossRef

Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, Honmura S, Yamashita K (1996) Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 19(11):1306–1307CrossRef

Ohira S, Inoue T, Shobayashi K, Iwao K, Fukushima M, Tanihara H (2015) Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci 56(6):3541–3548CrossRef

10.

Ishikawa K, Yoshida S, Kobayashi Y, Zhou Y, Nakama T, Nakao S, Sassa Y, Oshima Y, Niiro H, Akashi K, Kono T, Ishibashi T (2015) Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 56(2):932–946CrossRef

11.

Nakama T, Yoshida S, Ishikawa K, Kubo Y, Kobayashi Y, Zhou Y, Nakao S, Hisatomi T, Ikeda Y, Takao K, Yoshikawa K, Matsuda A, Ono J, Ohta S, Izuhara K, Kudo A, Sonoda KH, Ishibashi T (2017) Therapeutic effect of novel single-stranded RNAi agent targeting periostin in eyes with retinal neovascularization. Mol Ther Nucleic Acids 6:279–289CrossRef

12.

Kobayashi Y, Yoshida S, Zhou Y, Nakama T, Ishikawa K, Arima M, Nakao S, Sassa Y, Takeda A, Hisatomi T, Ikeda Y, Matsuda A, Sonoda KH, Ishibashi T (2016) Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy. Mol Vis 22:436–445PubMedPubMedCentral

13.

Ishikawa K, Yoshida S, Nakao S, Nakama T, Kita T, Asato R, Sassa Y, Arita R, Miyazaki M, Enaida H, Oshima Y, Murakami N, Niiro H, Ono J, Matsuda A, Goto Y, Akashi K, Izuhara K, Kudo A, Kono T, Hafezi-Moghadam A, Ishibashi T (2014) Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 28(1):131–142CrossRef

14.

Yoshida S, Ishikawa K, Asato R, Arima M, Sassa Y, Yoshida A, Yoshikawa H, Narukawa K, Obika S, Ono J, Ohta S, Izuhara K, Kono T, Ishibashi T (2011) Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 52(8):5670–5678CrossRef

15.

Kobayashi Y, Yoshida S, Zhou Y, Nakama T, Ishikawa K, Kubo Y, Arima M, Nakao S, Hisatomi T, Ikeda Y, Matsuda A, Sonoda KH, Ishibashi T (2016) Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin alphaV. Lab Investig 96(11):1178–1188CrossRef

16.

Kita T, Hata Y, Kano K, Miura M, Nakao S, Noda Y, Shimokawa H, Ishibashi T (2007) Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 56(1):231–238CrossRef

17.

Min SH, Lee TI, Chung YS, Kim HK (2006) Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol 20(3):162–165CrossRef

18.

Nakama T, Yoshida S, Ishikawa K, Kobayashi Y, Zhou Y, Nakao S, Sassa Y, Oshima Y, Takao K, Shimahara A, Yoshikawa K, Hamasaki T, Ohgi T, Hayashi H, Matsuda A, Kudo A, Nozaki M, Ogura Y, Kuroda M, Ishibashi T (2015) Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin. Gene Ther 22(2):127–137CrossRef

19.

Kudo A, Kii I (2018) Periostin function in communication with extracellular matrices. J Cell Commun Signal 12(1):301–308CrossRef

20.

Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N, Kudo A (2010) Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 285(3):2028–2039CrossRef

21.

Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118(1):98–104CrossRef

22.

Stamer WD, Clark AF (2017) The many faces of the trabecular meshwork cell. Exp Eye Res 158:112–123CrossRef

23.

Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS (2009) Extracellular matrix turnover and outflow resistance. Exp Eye Res 88(4):676–682CrossRef

24.

Norris RA, Potts JD, Yost MJ, Junor L, Brooks T, Tan H, Hoffman S, Hart MM, Kern MJ, Damon B, Markwald RR, Goodwin RL (2009) Periostin promotes a fibroblastic lineage pathway in atrioventricular valve progenitor cells. Dev Dyn 238(5):1052–1063CrossRef

25.

Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14(7):1239–1249CrossRef

26.

Chono I, Miyazaki D, Miyake H, Komatsu N, Ehara F, Nagase D, Kawamoto Y, Shimizu Y, Ideta R, Inoue Y (2018) High interleukin-8 level in aqueous humor is associated with poor prognosis in eyes with open angle glaucoma and neovascular glaucoma. Sci Rep 8(1):14533CrossRef

27.

SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY (2015) Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol 43(9):803–807CrossRef

Title: Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR
Authors: Keijiro Ishikawa
Ri-ichiro Kohno
Kenichiro Mori
Yusuke Murakami
Shintaro Nakao
Masato Akiyama
Shigeo Yoshida
Koh-Hei Sonoda
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Glaucoma
Cataract
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 3/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04574-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Foveal vasculature changes and nonperfusion in patients with diabetes types I and II with no evidence of diabetic retinopathy

Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study

Off-label use of bevacizumab for wet age-related macular degeneration in Europe

Optical coherence tomography analysis of patients with untreated diabetic macular edema

Scleral buckling—a brief historical overview and current indications

Structure–function relationship between Bruch’s membrane opening-minimum rim width and perimetry in open-angle glaucoma subtypes